Study of PMS777, a new type of acetylcholinesterase inhibitor, in human HepG2 cells. Comparison with tacrine and galanthamine on oxidative stress and mitochondrial impairment

Toxicology in Vitro

Volumn 20, Issue 6, 2006, Pages 824-831

  Ezoulin, M J M ^a   Dong, C Z ^a   Liu, Z ^a,c   Li, J ^d   Chen, H Z ^d   Heymans, F ^a   Lelievre L ^a   Ombetta, J E ^a   Massicot, F ^b  

^a Laboratoire de Pharmacochimie   (France)

^b Centre Universitaire des Saints Pères   (France)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d Medical University 2   (China)

Author keywords

Acetylcholinesterase inhibitor; Fluorescent probes; Galanthamine; HepG2; Oxidative stress; PAF antagonist; PMS777; Tacrine

Indexed keywords

BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; GALANTAMINE; GLUTATHIONE; MEMBRANE LIPID; PHOSPHOLIPID; PMS 777; REACTIVE OXYGEN METABOLITE; TACRINE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL MEMBRANE POTENTIAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LIVER TOXICITY; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; OXIDATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS;

CELL SURVIVAL; CHOLINESTERASE INHIBITORS; FURANS; GALANTAMINE; HUMANS; LIPID PEROXIDATION; LIVER; MEMBRANE POTENTIALS; MITOCHONDRIA; OXIDATIVE STRESS; PLATELET ACTIVATING FACTOR; TACRINE;

EID: 33745202817     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2006.01.002     Document Type: Article

References (40)

1. Aihara M., Ishii S., Kume K., and Shimizu T. Interaction between neurone and microglia mediated by platelet-activating factor. Genes Cells 5 (2000) 397-406
2. Arechabala B., Coiffard C., Rivalland P., Coiffard L.J., and de Roeck-Holtzhauer Y. Comparison of cytotoxicity of various surfactants tested on normal human fibroblast cultures using the neutral red test, MTT assay and LDH release. Journal of Applied Toxicology 19 (1999) 163-165
3. Belloc F., Dumain P., and Boisseau M.R. A flow cytometric method using Hoechst 33342 and propidium iodide for simultaneous cell cycle and apoptosis determination in unfixed cells. Cytometry 17 (1994) 59-65
4. Benoit G.G., Naud C.F., Simard M.A., and Astier A.L. Noninterference of cytochrome P4501A2 in the cytotoxicity of tacrine using genetically engineered V79 Chinese hamster cells for stable expression of the human or rat isoform and two human hepatocyte cell lines. Biochemical Pharmacology 53 (1997) 423-427
5. Blackard W.G., Sood G.K., Crowe D.R., and Fallon M.B. Tacrine. A cause of fatal hepatotoxicity?. Journal of Clinical Gastroenterology 26 (1998) 57-59
6. Chao J.C., and Chu C.C. Effects of Ginkgo biloba extract on cell proliferation and cytotoxicity in human hepatocellular carcinoma cells. World Journal of Gastroenterology 10 (2004) 37-41
7. Darvesh S., and Hopkins D.A. Differential distribution of butyryl-cholinesterase and acetylcholinesterase in the human thalamus. Journal of Comparative Neurology 11 (2003) 25-43
8. Darzynkiewicz Z., Bruno S., Del Bino G., Gorczyca W., Hotz M.A., Lassota P., and Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry 13 (1992) 795-808
9. Debbasch C., Pisella P.J., De Saint Jean M., Rat P., Warnet J.M., and Baudouin C. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved β-blockers on Chang conjunctival cells. Investigative Ophthalmology and Visual Science 42 (2001) 2525-2533
10. De Fries R., and Mitsuhashi M. Quantification of mitogen induced human lymphocyte proliferation: comparison of alamar blue assay to 3H-thymidine incorporation assay. Journal of Laboratory Analysis 9 (1995) 89-95
11. Dierickx P.J. Formation of reactive oxygen species in rat hepatoma-derived Fa32 cells to predict human toxicity. Toxicology In Vitro 16 (2002) 725-730
12. Ford J.M., Truman C.A., Wilcock G.K., and Roberts C.J.C. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clinical Pharmacology and Therapy 53 (1993) 691-695
13. Galisteo M., Rissel M., Sergent O., Chevanne M., Cillard J., Guillouzo A., and Lagadic-Gossman D. Hepatotoxicity of tacrine: occurrence of membrane fluidity alterations without involvement of lipid peroxidation. Journal of Pharmacology and Experimental Therapeutics 294 (2000) 160-167
14. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer's disease. Neurochemical Research 25 (2000) 1185-1190
15. Hammel P., Larrey D., Bernuau J., Kalafat M., Freneaux E., Babany G., Degott C., Feldmann G., Pessayre D., and Benhamou J. Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease. Journal of Clinical Gastroenterology 12 (1990) 329-331
16. Hebert L.E., Scherr P.A., Beckett L.A., Albert M.S., Pilgrim D.M., Chown M.J., Funkenstein H.H., and Evans D.A. Age-specific incidence of Alzheimer's disease in a community population. Journal of the American Medical Association 273 (1995) 1354-1359
17. Johnson C.N., Roland A., and Upton N. New symptomatic strategies in Alzheimer's disease. Drug Discovery Today 1 (2004) 13-19
18. Kubes P., Suzuki M., and Granger D.N. Platelet activating factor-induced microvascular dysfunction: role of adherent leukocytes. American Journal of Physiology 258 (1990) G158-G163
19. Lagadic-Gossman D., Rissel M., Le Bot M.A., and Guillouzo A. Toxic effects of tacrine on primary hepatocytes and liver epithelial cells in culture. Cell Biology and Toxicology 14 (1998) 361-373
20. Larson E.M., Doughman D.J., Gregerson D.S., and Obritsch W.F. A new, simple, non-radioactive, non-toxic in vitro assay to monitor corneal endothelial cell viability. Investigative Ophthalmology and Visual Science 38 (1997) 1929-1933
21. Le Texier L., Favre E., Redeuilh C., Blavet N., Bellahsene T., Dive G., Pirotzky E., and Godfroid J.J. Structure-activity relationship in platelet-activating factor (PAF). 7. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors. Synthesis and PAF-antagonistic activity. Journal of Lipid Mediators Cell Signalling 13 (1996) 189-205
22. Le Texier L., Favre E., Ronzani N., Massicot F., Blavet N., Pirotzky E., and Godfroid J.-J. Structure-activity relationships in platelet-activating factor (PAF). 8. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors: anti-acetylcholinesterase activity and comparative SAR. Journal of Lipid Mediators Cell Signalling 13 (1996) 207-222
23. Maciorowski Z., Delic Z., Padoy E., Dubray B., Cosset J.-M., Dumont J., Magdelena H., and Vielh P. Comparative analysis of apoptosis measured by Hoechst and flow cytometry in non-Hodgkin's lymphomas. Cytometry 32 (1998) 44-50
24. Mansouri A., Haouzi D., Descatoire V., Demeilliers C., Vadrot N., Fromenty B., Feldmaann G., Pessayre D., and Berson A. Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver. Hepatology 38 (2003) 715-725
25. Mannens G.S., Snel C.A., Hendrickx J., Verhaeghe T., Le Jeune L., Bode W., Van Beijsterveldt L., Lavrijsen K., Leempoels J., Van Osselaer N., Van Peer A., and Meuldermans W. The metabolism and excretion of galanthamine in rats, dogs, and humans. Drug Metabolism and Disposition 30 (2002) 553-563
26. Medina-Diaz I.M., and Elizondo G. Transcriptional induction of CYP3A4 by o,p′-DDT in HepG2 cells. Toxicology Letters 157 (2005) 41-47
27. Mesulam M.-M., Guillozet A., Shaw P., Levey A., Duysen E.G., and Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 110 (2002) 627-639
28. Monteith D.K., Emmerling M.R., Garvin J., and Theiss J.C. Cytotoxicity study of tacrine, structurally and pharmacologically related compounds using rat hepatocytes. Drug and Chemical Toxicology 19 (1996) 71-84
29. Osseni R.A., Debbasch C., Christen M.O., Rat P., and Warnet J.-M. Tacrine-induced reactive oxygen species in a human liver cell line: the role of anethole dithiolethione as a scavenger. Toxicology in Vitro 13 (1999) 683-688
30. Parker M.A., Bazan H.E.P., Marcheselli V., Rodriguez de Turco E.B., and Bazan N.G. Platelet-activating factor induces permeability transition and cytochrome c release in isolated brain mitochondria. Journal of Neuroscience Research 69 (2002) 39-50
31. Pouzaud F., Christen M.O., Warnet J.-M., and Rat P. In vitro discrimination of fluoroquinolones toxicity on tendon cells: involvement of oxidative stress. Journal of Pharmacology and Experimental Therapeutics 308 (2004) 394-402
32. Rat P., Korwin-zmijowska C., Warnet J.M., and Adolphe M. New in vitro fluorimetric microtitration assays for toxicological screening of drugs. Cellular Biology and Toxicology 10 (1994) 329-337
33. Rat P., Osseni R., Christen M.O., Thevenin M., Warnet J.M., and Adolphe M. Microtitration fluorimetric assays on living cells: news tools for screening in cell pharmacology. In: Van Zuphen L.F.M., and Balls M. (Eds). Animal Alternative, Welfare and Ethic (1997), Elsevier, Paris 813-824
34. Rodriguez-Antona C., Donato M.T., Boobis A., Edwards R.J., Watts P.S., Castell J.V., and Gomez-Lechon M.J. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32 (2002) 505-520
35. Watkins P.B., Zimmerman H.J., Knapp M.J., Gracon S.I., and Lewis K.W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. Journal of the American Medical Association 271 (1994) 992-998
36. Wilkening S., Stahl F., and Bader A. Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties. Drug Metabolism and Disposition 31 (2003) 1035-1042
37. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochemical Medicine 15 (1976) 212-216
38. Yamakawa Y., Takano M., Patel M., Tien N., Takada T., and Bulkley G.B. Interaction of platelet activating factor, reactive oxygen species generated by xanthine oxidase, and leukocytes in the generation of hepatic injury after shock/resuscitation. Annals of Surgery 231 (2000) 387-398
39. Zhao Q., Brett M., Van Osselaer N., Huang F., Raoult A., Van Peer A., and Verhaeghe T. Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects. Journal of Clinical Pharmacology 42 (2002) 1002-1010
40. Zhu P., DeCoster M.A., and Bazan N.G. Interplay among platelet-activating factor, oxidative stress, and group I metabotropic glutamate receptors modulates neuronal survival. Journal of Neuroscience Research 77 (2004) 525-531